Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund | Janus Henderson Investors
For financial professionals in the Middle East

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE0002141913

NAV
USD 91.64
As of 2026/11/04

1-Day Change
USD 2.84 (3.20%)
As of 2026/11/04

Morningstar Rating

As of 2026/09/30

Overview

Investment objective

This global health care fund seeks consistent returns by investing in companies addressing unmet medical needs or making the health care system more efficient. We balance the portfolio across pharmaceuticals, biotechnology and services/devices sub-sectors in an effort to achieve similar or lower volatility relative to our peers.

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.
Potential investors must read the prospectus, and where relevant, the key investor information document before investing.
This website is a Marketing Communication and does not qualify as an investment recommendation.

About this fund

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care
Past performance does not predict future returns. 
 

Portfolio Management

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Past performance does not predict future returns. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
Fee Information
Initial Charge 2.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2025/12/31)
1.55%

Portfolio

Top Holdings (As of 2026/09/30)
Holding % of Fund
Eli Lilly & Co 9.62
Johnson & Johnson 7.79
AbbVie Inc 4.94
UnitedHealth Group Inc 4.27
AstraZeneca PLC 3.71
Thermo Fisher Scientific Inc 3.35
Novartis AG (ADR) 2.73
Roche Holding AG 2.68
Argenx SE (ADR) 2.45
Merck & Co Inc 2.35
TOTAL 43.89

No data found at this time

No data found at this time

No data found at this time

No data found at this time

Documents

  • The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • Past performance does not predict future returns.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
  • Funds incur costs as a necessary part of buying and selling the underlying investments, these are otherwise known as portfolio transaction costs, and include charges such as broker commission and Stamp Duty.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved.
  • Summary of Investor rights
  • Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation.
  • Information on compliance with EU Sustainability related disclosures can be found here.
  • For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.
  • The Legal Entity Identifier for this product is 5493002MVUQOZF2KCA11.